COPENHAGEN, Denmark, October 31, 2025 – Bavarian Nordic A/S has announced the securing of a significant joint procurement contract awarded by the European Commission through its Health Emergency Preparedness and Response Authority (HERA). This new and larger framework agreement allows for the purchase of up to 8 million doses of its MVA-BN^® smallpox/mpox vaccine over the next four years, reinforcing Europe’s preparedness and response capacity against high-consequence infectious disease threats. This deal directly replaces a prior agreement from 2022 and incorporates participation by 20 EU member states as well as additional European countries, substantially broadening the geographic and population coverage for public health interventions.

Paul Chaplin, Bavarian Nordic’s President and CEO, highlighted the strategic importance of the contract, noting, “We are pleased to extend our collaboration with HERA to facilitate broad access to our smallpox and mpox vaccine across the region. This agreement is a recognition of public health security as part of the resilience the EU is building to unify against threats on a larger scale, and we are proud to be part of efforts to safeguard Europe’s citizens against life-threatening diseases.”

The MVA-BN^® vaccine was selected in response to ongoing healthcare system needs for effective countermeasures against both smallpox and mpox (formerly known as monkeypox), diseases that have seen periodic resurgences and which require structured immunization and preparedness planning. HERA’s expanded contracting brings clear benefits for inventory management, strategic stockpiling, and rapid, coordinated deployment during outbreaks, supporting Europe’s hospital networks, centralized procurement authorities, and public health agencies.

This procurement framework ensures continuous vaccine access, which is vital as Europe works to reinforce its health system resilience against both emerging and re-emerging infectious disease risks. The agreement allows for immediate and scalable distribution as needs arise, addressing the requirements of healthcare facilities, emergency care operations, infection control programs, and vaccination clinics within diverse health system contexts. With additional participant countries underscoring pan-European collaboration, the framework enables efficient supply logistics and harmonized response protocols for crisis scenarios, clinical need, and surge capacity.

From a business and hospital management perspective, this contract is highly strategic. It provides security of supply in times of potential crisis and supports planful forecasting and inventory decisions at hospital, regional, and national levels. It also exemplifies the continued development of public-private partnerships that leverage industrial-scale biomanufacturing and supply chain strengths. Such procurement arrangements benefit not only clinical leadership and procurement professionals—who can rely on greater certainty over vaccine availability—but also facilitate coordinated mass immunization campaigns and contingency planning for healthcare administrators. In an era marked by frequent cross-border health threats, and with the mpox outbreak of recent years as a backdrop, the EU’s actions through HERA may serve as a model for future collaborative acquisition and distribution of critical countermeasures.

This agreement will further align with broader hospital infection control, critical care, and emergency preparedness objectives, contributing significantly to Europe’s overall healthcare security architecture while providing a long-term roadmap for regional cooperation, resource deployment, and resilience against currently known and future infectious disease threats.